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Background: Most Agouti viable yellow (Avy) mice display constitutive expression of agouti protein, which acts as an
inverse agonist at the melanocortin receptor 4 (Mc4r), resulting in adult-onset obesity as well as an altered sensitivity to
some drugs of abuse. We investigated the influence of excessive agouti expression on open-field locomotor response
to daily 0.5 mg/kg (−)-freebase nicotine injections in 27 early adolescent and 27 young adult male Avy/a and a/a mice,
and assessed the effects of nicotine administration (0.5 mg/kg) followed by open-field testing on serum corticosterone
levels in a separate group of 25 young adult male Avy/a and a/a mice.
Findings: Young adult Avy/a mice displayed pronounced nicotine-induced hypolocomotion (a 24% reduction in
distance traveled) compared to their a/a littermates. Early adolescent Avy/a mice did not differ from their a/a littermates
or saline-matched controls in locomotion following nicotine administration. Young adult Avy/a mice also displayed
increased thigmotaxis (a 5% increase in time spent outside the center of the apparatus) on the first day of nicotine
administration as compared to saline-matched controls, while a/a mice did not. An increase in serum corticosterone
levels 20 minutes after nicotine injection in a separate group of young adult male mice (n = 25) was proportionally
similar between Avy/a and a/a mice.
Conclusions: Overall, the results suggest an age- and epigenotype- or genotype-specific response to nicotine
administration in young adult male Avy/a mice. It appears the Avy/a locomotor and thigmotaxic responses to acute
nicotine administration are not mediated solely by hypothalamic-pituitary-adrenal (HPA) axis stimulation.
Keywords: Nicotine, Agouti viable yellow, Melanocortin receptor 4, Locomotion, Thigmotaxis, Corticosterone,
Hypothalamic-pituitary-adrenalFindings
Introduction
In wild-type (WT) mice, the agouti gene is transiently
expressed during hair growth and encodes a signaling
molecule that creates a subapical yellow band on each,
otherwise brown or black, hair [1]. This yellow and black
amalgamation results in the agouti coat color of the
WT mouse. Avy/a mice have a dominant mutation due
to a retrotransposon insertion in the agouti allele that
results in constitutive agouti expression, leading to the
expression of yellow fur in the majority of animals [2].
Other littermates with the background genotype (a/a* Correspondence: djv4@psu.edu
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reproduction in any medium, provided the orhomozygotes) have a loss-of-function mutation in the
agouti gene, which results in black coats [3]. In yellow
and mottled yellow Avy/a mice, the agouti gene is
expressed ectopically in all tissues, and this over-
expression is associated with a phenotype that includes
obesity, diabetes, and tumorigenesis [4]. a/a mice, on
the other hand, have no ectopic expression of agouti,
and thus do not display obesity or the other comorbidi-
ties that their yellow Avy/a littermates do [5]. Agouti
expression appears to be modified epigenetically in Avy/a
mice, where hypomethylation at the Agouti locus is corre-
lated with a higher proportion of yellow fur, and the con-
comitant metabolic syndrome, while methylation at the
locus results in a pseudoagouti (similar to WT) coat color
and an absence of the metabolic syndrome [6].
The adult-onset metabolic syndrome in Avy/a mice is
thought to be mediated at least in part by the agouti
protein acting as an inverse agonist at the Mc4r [7],al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Interestingly, the melanocortin system also appears to be
involved in the response to some addictive drugs. For
example, melanocortins antagonize the neurobiological
effects of opiates, and down regulation of Mc4rs may be
integral to the development of opiate addiction [10].
Mc4rs also may be associated with the rewarding effects
of cocaine, as chronic cocaine administration increases
Mc4r expression in the adult male rat striatum via a
dopamine-dependent mechanism [11]. Male Ay mice
(which also exhibit melanocortin receptor antagonism)
demonstrate a reduced locomotor response to repeated
cocaine administration compared to C57BL/6 (B6) mice,
which suggests that melanocortin receptors may contrib-
ute to the behavioral effects of cocaine [12]. Addition-
ally, Mc4r agonists like melanotan increase ethanol
intake in adult male and female rats, while Mc4r antago-
nists decrease intake [13].
Nicotine also may interact with or act on the same
neurobiological systems as drugs like morphine [14],
cocaine [15], and alcohol [16]. The result of these interac-
tions or similarities in mechanism can sometimes be very
apparent in the epidemiology of human drug use. For ex-
ample, rates of cigarette smoking are often much higher in
cocaine-dependent [17] individuals and alcohol-dependent
[18] individuals.
Little research has been reported, however, on the
relationship between nicotine and the melanocortin
system besides investigations into the role melanocortins
may play in the anorectic effects of nicotine e.g. [19]. To
examine how melanocortin receptor antagonism might
influence behavioral responses to nicotine in Avy/a mice,
we repeatedly administered 0.5 mg/kg (−)-freebase nico-
tine to young adult and early adolescent male Avy/a mice
as well as their a/a littermates, and measured their loco-
motion in an open-field apparatus. The obesity pheno-
type in Avy/a mice emerges in late adolescence to early
adulthood, which suggests there may be age-related
differences in the effect of constitutive agouti expression
across the Avy/a lifespan [20]. Thus, we expected there
might be informative changes in locomotor responses to
nicotine in early adolescent versus young adult mice.
After observing hypolocomotion following nicotine
administration in young adult Avy/a mice, we further
explored this age-specific effect by analyzing the time
spent in the center vs. the periphery of the apparatus in
young adult mice to determine thigmotaxis (the propen-
sity to stay close to the walls of an open field), a pur-
ported measure of rodent anxiety [21]. Based on the
results of thigmotaxis tests, nicotine administration
seemed to have an anxiogenic effect on young adult Avy/a
mice on the first day of treatment. Because anxiogenic
events in mice are often associated with corticosterone
secretion via hypothalamic-pituitary-adrenal (HPA) axisactivation [22], we hypothesized that this anxiogenic effect
of nicotine might be associated with increased cortico-
sterone secretion as well. To test this hypothesis, we
assayed serum corticosterone in a subgroup of young
adult male Avy/a and a/a mice following their first expos-
ure to nicotine.
Methods
Seventy-nine male Avy/a (n =39) and a/a mice (n =40)
were descendants of mice provided by Dr. Randy Jirtle
(Duke University, Durham, NC). All Avy/a mice had
either yellow or mottled yellow coat colors. After wean-
ing at postnatal day (PND) 28, adolescents (n = 27)
began behavioral testing at 29–31 PND, while behavioral
testing for young adult mice (n = 27) took place between
PND 50 and PND 70. This age range was chosen be-
cause by this point Avy/a mice have begun to display
much greater weight gain than siblings that don’t have
the Avy mutation [15]. Thus, we hypothesized that age-
related differences in the effect of constitutive agouti
expression may emerge during this time period. During
behavioral testing, animals received a subcutaneous (s.c.)
injection of 0.5 mg/kg (−)-freebase nicotine in 0.9%
saline or vehicle 5 minutes before being placed in the
testing apparatus, a 40 × 40 × 40 cm white activity box.
The dosage of 0.5 mg/kg was chosen because it is gener-
ally well tolerated by mice and results in mild changes in
locomotion [23]. Animals were tested within an hour of
onset of the dark cycle under dim red lights. Mice were
habituated to the apparatus for 3 consecutive days by
being placed in the box and allowed to explore for 15 -
minutes. Then, for 2 days mice received saline injections
(s.c.) before being placed in the apparatus for 15 minutes
to habituate to the injection procedure. For the 5 treat-
ment days, mice received either saline or nicotine and
were placed in the apparatus for 15 minutes. Activity
was monitored using video tracking software (Anymaze
4.20, Stoelting, USA). Locomotor response to nicotine
was measured by mean distance traveled in meters.
Thigmotaxis was measured in young adult animals by
assessing the distance traveled outside the center of the
apparatus and dividing by the total distance traveled
[24]. This calculation was used to control for the effects
a reduction in locomotion itself might have on thigmo-
taxis. The center region of the apparatus was defined as
the central 20 × 20 cm area.
Corticosterone assessment also took place between
PND 50 and PND 70 in a separate group of young adult
male mice (n = 25). These mice were sacrificed via cervical
dislocation following their first nicotine injection (all mice
received nicotine treatment) and subsequent 15-minute
locomotion assay; trunk blood was collected. Samples sat
at room temperature for 15 minutes, then were centri-
fuged at 1500 × g. Serum was aliquoted and frozen at
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sterone was determined using an enzyme immmunosor-
bent assay (EIA; Arbor Assays, Ann Arbor, MI, USA)
in the Biomarker Core Laboratory in the Department of
Biobehavioral Health at The Pennsylvania State University.
The assay sensitivity was 18.6 pg/mL; the limit of detec-
tion was 16.9 pg/mL.
Locomotion was analyzed using a 4-way repeated mea-
sures ANOVA for Age x Genotype x Treatment x Treat-
ment Day. A 3-way repeated measures ANOVA for
Genotype x Treatment x Treatment Day was used to
analyze thigmotaxis in young adult animals. Serum cor-
ticosterone levels were analyzed using a 2-way ANOVA
for Genotype x Treatment. Differences between saline
and drug-treated controls were tested using 2-sample
t-tests. Findings were considered statistically significant
at p < 0.05. Data were analyzed using SAS (version 9.2;
Cary, North Carolina) statistical software.
All animal experiments were approved by the Pennsyl-
vania State University Institutional Animal Care and Use
Committee (IACUC #’s 29898 & 33133).Figure 1 Adolescent locomotion following nicotine
administration. Nicotine (0.5 mg/kg) was administered for 5
consecutive days to a/a mice (a), and Avy/a mice (b). Data are
presented as mean distance traveled in meters ± SE; n = 6–8
per group.Results
Overall 4-way repeated measures ANOVA showed a sig-
nificant effect of Age x Genotype x Treatment (F1, 46 =
6.21, p < 0.05) on locomotor activity. Nicotine adminis-
tration had no noticeable effect on locomotion in adoles-
cent mice (Figure 1). In young adult mice, a/a mouse
locomotion was not influenced by nicotine administra-
tion (Figure 2a) while Avy/a mice displayed hypolocomo-
tion after nicotine treatment throughout the course of
testing period (Figure 2b). Nicotine-treated young adult
Avy/a mice were significantly different than their saline-
matched controls on Day 1 (t10 = −4.06, p < 0.01), Day 2
(t10 = −2.26, p < 0.05), Day 3 (t10 = −2.52, p < 0.05), Day 4
(t10 = −3.44, p < 0.01), and Day 5 (t10 = −2.35, p < 0.05).
Nicotine did not induce thigmotaxis on any day in
young adult a/a animals (Figure 3a). On most days,
young adult Avy/a mice showed no difference from their
a/a littermates in thigmotaxis (3-way repeated measures
ANOVA p > 0.05). However, on Day 1, nicotine-treated
young adult Avy/a mice displayed significant thigmotaxis
(Figure 3b) as compared to saline-matched controls
(t = 2.97, p < 0.05). There were significant main effects of
Treatment (F1, 21 = 19.42, p < 0.001) and Genotype
(F1, 21 = 9.58, p < 0.01) on serum corticosterone levels in
young adult mice. Both Avy/a (t9 = −2.38, p < 0.05) and
a/a (t8 = 3.84, p < 0.01) mice displayed increased cortico-
sterone levels after nicotine administration in compari-
son to saline-matched controls (Figure 4). However, the
magnitude of the corticosterone increase after nicotine
administration was not significantly different between
Avy/a and a/a mice.Discussion
Hypolocomotion after nicotine administration is com-
mon in mice at increasing doses, and is a potential indi-
cator of sensitivity to the toxicity of nicotine [23,25].
That young adult Avy/a mice display such a robust loco-
motor depression that persists over the course of the
testing period suggests that they are especially sensitive
to nicotine administration at the 0.5 mg/kg dose. The
observation that early adolescent Avy/a mice demon-
strated no such effect may indicate that the emergence
of the obesity phenotype in Avy/a mice, which occurs
around the time of puberty [20], also corresponds with
changes in sensitivity to the effects of nicotine adminis-
tration. As it is thought that Avy/a obesity is driven to a
large degree by Mc4r antagonism, it is plausible that
Mc4r antagonism also plays a role in increased nicotine
sensitivity.
However, adolescence in general represents a time of
altered sensitivity to the effects of nicotine in mice. For
example, adolescent male mice are more responsive than
Figure 2 Young adult locomotion following nicotine
administration. Nicotine (0.5 mg/kg) was administered for 5
consecutive days to a/a mice (a), and Avy/a mice (b). Data are
presented as mean distance traveled in meters ± SE; n = 5–8 per
group. * p < .05, ** p < 0.01 significantly different from
saline-matched controls.
Figure 3 Thigmotaxis in young adult mice following nicotine
administration. Nicotine (0.5 mg/kg) was administered for 5
consecutive days to a/a mice (a), and Avy/a mice (b). For graphical
presentation, thigmotaxis was calculated as 1−
distance traveled outside center of apparatus
total distance traveled . Data are presented as mean ± SE;
n = 5–8 per group. * p < 0.05 significantly different from
saline-matched controls.
Figure 4 Serum corticosterone following nicotine (0.5 mg/kg)
administration in young adult Avy/a and a/a mice. n = 6–7 per
group. *p < 0.05, ** p < 0.01 significantly different from saline-matched
controls of the same genotype.
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by conditioned place preference [26], and adolescent
male mice are less sensitive than adults to the locomotor
depression and hypothermia that occurs with higher
doses of nicotine [27]. Thus, it may be that an altered
response to nicotine in adolescent Avy/a mice obscures
the influence the Avy mutation and its downstream
effects (e.g. Mc4r antagonism) have on nicotine sensitiv-
ity until adulthood.
It must also be recognized that the nature of the
agouti mutation is complex, and differences in behavior
between Avy/a and a/a animals do not necessarily in-
volve ectopic expression of the agouti protein. For
example, the agouti (A) gene is found on chromosome 2
[2], and a polymorphism in the coding portion of the α4
nicotinic receptor gene (also found on chromosome 2 in
the mouse) has been observed to affect sensitivity
to nicotine-induced seizures [28,29]. Nicotine-induced
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tine, and often strains that display greater susceptibility
to seizures exhibit hypolocomotion at lower doses of
nicotine than less-sensitive strains [30,31]. Thus, future
work should explore the effects of the agouti mutation
on other nearby genes, as such effects could potentially
alter sensitivity to nicotine administration.
The thigmotaxis displayed by young adult male Avy/a
mice after their first nicotine administration appears to
indicate an anxiogenic response to initial nicotine ad-
ministration at the 0.5 mg/kg dose. While the hypoloco-
motion and thigmotaxis of young adult Avy/a mice on
the first day of treatment are likely related, it is import-
ant to note that the thigmotaxis does not appear to be a
direct result of reduced locomotion (as this was con-
trolled for in the calculation). Being placed in an open-
field apparatus is considered a stressor for mice; it re-
sults in HPA axis activation and corticosterone secretion
[22]. Nicotine administration in mice also results in cor-
ticosterone secretion [32]. Thus, we reasoned that the
anxiety behavior in Avy/a mice might be associated with
heightened levels of corticosterone secretion. A disparity
in HPA axis activation, however, doesn’t appear to ex-
plain the differences in nicotine-induced thigmotaxis
noted between young adult Avy/a and a/a mice. While
Avy/a mice did display an elevation in serum cortico-
sterone levels, the magnitude of the increase was similar
to that displayed by a/a mice.
It is also possible that young adult Avy/a mice exhibit
an enhanced sensitivity of HPA pathways and/or down-
stream targets in comparison to their a/a littermates,
potentially as a result of Mc4r antagonism from agouti
protein expression. A similar hypothesis has been sug-
gested to explain a heightened sensitivity to the adminis-
tration of corticotropin-releasing factor in Mc4r-null
mice [9]. Lethal yellow (Ay) mice, which also display ex-
cessive agouti expression and Mc4r inverse agonism,
show greater reactivity to restraint and injection stress
than B6, despite having comparable corticosterone levels
after experiencing the stressor [33]. Thus, a compensa-
tory enhancement of corticosterone sensitivity due to
Mc4r antagonism seems plausible, but remains specula-
tive until it can be tested with further research.
Conclusion
Understanding the nature of aversive reactions to nico-
tine is important because the degree of aversion human
smokers experience during their initial experience with
smoking is a predictor of whether or not they continue
to smoke [34,35]. The experiments presented here indi-
cate that Avy/a mice may provide a unique model in
which to study the aversive effects of nicotine and the
role of the melanocortin system in the effects of nico-
tine. Additionally, the age-specific aspects of the resultsdiscussed above are of interest, as the vast majority of
adult smokers begin smoking during adolescence [36].
Because adolescent Avy/a mice appear to be less sensitive
to nicotine-induced hypolocomotion than adult Avy/a
mice, the strain may represent a useful tool for studying
differences between adult and adolescent responses to
nicotine. Future research should attempt to replicate
these findings; if successful it would be informative to
further explore the effect using methods of nicotine ad-
ministration that are more relatable to human nicotine
consumption, such as intravenous self-administration. A
more thorough exploration of the dosages that produce
this aversive reaction would also be essential. Addition-
ally, the interpretation of the anxiogenic effects seen
here would benefit from additional experiments using al-
ternative methodologies, such as the social interaction
test or novel object exploration, in order to affirm the
anxiogenic nature of the response. Finally, it may be
valuable to explore the neurobiological basis of the
strong reaction to nicotine administration seen here in
young adult Avy/a mice.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MD, DV, and JG contributed to the conception and design of the study and
the analysis and interpretation of the data. MD drafted the manuscript. All
authors were involved in the collection and interpretation of the data and
contributed to revisions to the final manuscript. All authors read and
approved the final manuscript.
Author details
1Department of Biobehavioral Health, The Pennsylvania State University, 219
Biobehavioral Health Building, 16802 University Park, PA, USA. 2Neuroscience
Program, The Pennsylvania State University, 219 Biobehavioral Health
Building, 16802 University Park, PA, USA. 3Genetics Program, Chandlee
Laboratory, The Pennsylvania State University, 219 Biobehavioral Health
Building, 16802 University Park, PA, USA.
Received: 7 August 2013 Accepted: 23 November 2013
Published: 1 December 2013
References
1. Waterland RA, Jirtle RL: Transposable elements: targets for early
nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003,
23:5293–5300.
2. Duhl DMJ, Vrieling H, Miller KA, Wolff GL, Barsh GS: Neomorphic agouti
mutations in obese yellow mice. Nat Genet 1994, 8:59–65.
3. Bultman SJ, Michaud EJ, Woychik RP: Molecular characterization of the
mouse agouti locus. Cell 1992, 71:1195–1204.
4. Wolff GL, Roberts DW, Galbraith DB: Prenatal determination of obesity,
tumor susceptibility, and coat color pattern in viable yellow (Avy/a)
mice. J Hered 1986, 77:151–158.
5. Wolff GL, Pitot HC: Variation of hepatic malic enzyme capacity with
hepatoma susceptibility in mice of different genotypes. Cancer Res 1972,
32:1861–1863.
6. Dolinoy DC, Huang D, Jirtle RL: Maternal nutrient supplementation
counteracts bisphenol A-induced DNA hypomethylation in early
development. Proc Natl Acad Sci USA 2007, 104:13056–13061.
7. Voisey J, Van Daal A: Agouti: from mouse to Man, from skin to Fat.
Pigment Cell Res 2001, 15:10–18.
8. Fan WF, Boston BA, Kesterson RA, Hruby VJ, Cone RD: Role of
melanocortinergic neurons in feeding and the agouti obesity syndrome.
Nature 1997, 385:165–168.
Dingman et al. BMC Research Notes 2013, 6:497 Page 6 of 6
http://www.biomedcentral.com/1756-0500/6/4979. Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaoloff KA, Fisher SL, Burn P,
Palmiter RD: Response of melanocortin-4 receptor-deficient mice to
anorectic and orexigenic peptides. Nat Genet 1999, 21:119–122.
10. Alvaro JD, Tatro JB, Quillan JM, Fogliano M, Eisenhard M, Lerner MR, Nestler EJ,
Duman RS: Morphine down-regulates melanocortin-4 receptor expression
in brain regions that mediate opiate addiction. Mol Pharmacol 1996,
50:583–591.
11. Alvaro JD, Taylor JR, Duman RS: Molecular and behavioral interactions
between central melanocortins and cocaine. J Pharmacol Exp Ther 2003,
304:391–399.
12. Hsu R, Taylor JR, Newton SS, Alvaro JD, Haile C, Han G, Hruby VJ, Nestler EJ,
Duman RS: Blockade of melanocortin transmission inhibits cocaine
reward. Eur J Neurosci 2005, 21:2233–2242.
13. Navarro M, Cubero I, Chen AS, Chen HY, Knapp DJ, Breese GR, Marsh DJ,
Thiele TE: Effects of melanocortin receptor activation and blockade on
ethanol intake: a possible role for the melanocortin-4 receptor. Alcohol
Clin Exp Res 2005, 29:949–957.
14. Davenport KE, Houdi AA, Van Loon GR: Nicotine protects against μ-opioid
receptor antagonism by β-funaltrexamine: evidence for nicotine-induced
release of endogenous opioids in brain. Neurosci Lett 1990, 113:40–46.
15. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL:
Synergistic interactions between nicotine and cocaine or
methylphenidate transporter inhibitor. Synapse 2000, 38:432–437.
16. Soderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA: Nicotinic
mechanisms involved in the dopamine activating and reinforcing
properties of ethanol. Behav Brain Res 2000, 113:85–96.
17. Budney AJ, Higgins ST, Hughes JR, Bickel WK: Nicotine and caffeine use in
cocaine-dependent individuals. J Subst Abuse Treat 1993, 5:117–130.
18. DiFranza JR, Guerrera MP: Alcoholism and smoking. J Stud Alcohol 1990,
51:130–135.
19. Mineur YS, Abizaid A, Rao Y, Salas R, DiLeone RJ, Gundisch D, Diano S,
DeBiasi M, Horvath TL, Gao XB, Picciott MR: Nicotine decreases food intake
through activation of POMC neurons. Science 2011, 332:1330–1332.
20. Wolff GL: Influence of maternal phenotype on metabolic differentiation
of agouti locus mutants in the mouse. Genetics 1977, 88:529–539.
21. Grossen NE, Kelley MJ: Species-specific behavior and acquisition of
avoidance behavior in rats. J Comp Physiol Psychol 1972, 81:307–310.
22. Anisman H, Hayley S, Kelly O, Borowski T, Merali Z: Psychogenic,
neurogenic, and systemic stressor effects on plasma corticosterone and
behavior: mouse strain-dependent outcomes. Behav Neurosci 2001,
115:443–454.
23. Risinger FO, Oakes RA: Nicotine-induced conditioned place preference
and conditioned place aversion in mice. Pharmacol Biochem Behav 1995,
51:457–461.
24. Simon P, Dupuis R, Costentin J: Thigmotaxis as an index of anxiety in
mice. Influence of dopaminergic transmission. Behav Brain Res 1994,
61:59–64.
25. Marks MJ, Stitzel JA, Collins AC: Genetic influences on nicotine responses.
Pharmacol Biochem Behav 1989, 33:667–678.
26. Kota D, Martin BR, Robinson SE, Damaj MI: Nicotine dependence and
reward differ between adolescent and adult male mice. J Pharmacol Exp
Ther 2007, 322:399–407.
27. Lopez MF, Simpson DD, White NM, Randall CL: Age- and sex-related differ-
ences in alcohol and nicotine effects in C57BL/6J mice. Addict Biol 2003,
8:419–427.
28. Stitzel JA, Jimenez M, Marks MJ, Tritto T, Collins AC: Potential role of the
alpha4 and alpha6 nicotinic receptor subunits in regulating nicotine-
induced seizures. J Pharmacol Exp Ther 2000, 293:67–74.
29. Stitzel JA, Dobelis P, Jimenez M, Collins AC: Long sleep and short sleep
mice differ in nicotine-stimulated 86Rb + efflux and alpha4 nicotinic
receptor subunit cDNA sequence. Pharmacogenetics 2001, 11:331–339.
30. O’Neill HC, Laverty DC, Patzlaff NE, Cohen BN, Fonck C, McKinney S,
McIntosh JM, Lindstrom JM, Lester HA, Grady SR, Marks MJ: Mice
expressing the ADNFLE valine 287 leucine mutation of the Β2 nicotinic
acetylcholine receptor subunit display increased sensitivity to acute
nicotine administration and altered presynaptic nicotinic receptor
function. Pharmacol Biochem Behav 2013, 103:603–621. doi.
31. Salas R, Cook KD, Bassetto L, De Biasi M: The alpha3 and beta4 nicotinic
acetylcholine receptor subunits are necessary for nicotine-induced
seizures and hypolocomotion in mice. Neuropharmacology 2004,
47:401–407.32. Freund RK, Martin BJ, Jungschaffer DA, Ullman EA, Collins AC: Genetic
differences in plasma corticosterone levels in response to nicotine
injection. Pharmacol Biochem Behav 1988, 30:1059–1064.
33. De Souza J, Butler AA, Cone RD: Disproportionate inhibition of feeding in
A(y) mice by certain stressors: a cautionary note. Neuroendocrinology
2000, 72:126–132.
34. Kozlowski LT, Harford MR: On the significance of never using a drug: an
example from cigarette smoking. J Abnorm Psychol 1976, 85:433–434.
35. Silverstein B, Kelly E, Swan J, Kozlowski LT: Physiological predisposition
toward becoming a cigarette smoker: experimental evidence for a sex
difference. Addict Behav 1982, 7:83–86.
36. Centers for Disease Control and Prevention: Preventing tobacco use
among young people: a report of the surgeon general. MMWR Recomm
Rep 1994, 43:1–10.
doi:10.1186/1756-0500-6-497
Cite this article as: Dingman et al.: Age-specific locomotor response to
nicotine in yellow and mottled yellow Avy/a mice. BMC Research Notes
2013 6:497.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
